EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma

Rebecca Wenling Zeng, Christen En Ya Ong, Elden Yen Hng Ong, Charlotte Hui Chung, Wen Hui Lim, Jieling Xiao, Pojsakorn Danpanichkul, Jia Hao Law, Nicholas Syn, Douglas Chee, Alfred Wei Chieh Kow, Sung Won Lee und 13 weitere

Clinical Gastroenterology and Hepatology · 2024-12 · 22 (12) · 2394-2402.e15

DOI: 10.1016/j.cgh.2024.06.026 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-12. Verfasst von Rebecca Wenling Zeng und 24 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although the burden of alcohol-associated hepatocellular carcinoma (HCC) is increasing with rising alcohol consumption, clinical presentation and outcomes of alcohol-associated HCC have not been systematically assessed. We aimed to determine the prevalence, clinical characteristics, surveillance rates, treatment allocation, and outcomes of alcohol-associated HCC. METHODS: Medline and Embase were searched from inception to January 2023. Proportional data were analyzed using a generalized linear mixed model. The odds ratio (OR) or mean difference comparing alcohol-associated HCC and other causes was obtained with pairwise meta-analysis. Survival outcomes were evaluated using a pooled analysis of hazard ratios. RESULTS: Of 4824 records identified, 55 articles (86,345 patients) were included. Overall, 30.4% (95% confidence interval [CI], 24.0%-37.7%) of HCC was alcohol associated, with the highest proportion in Europe and the lowest in the Americas. People with alcohol-associated HCC were more likely male but were similar in age and comorbidities compared with other causes. A total of 20.8% (95% CI, 11.4%-34.9%) of people with alcohol-associated HCC underwent surveillance compared with 35.0%, 31.6%, and 21.4% in hepatitis B virus, hepatitis C virus, and metabolic dysfunction-associated HCC, respectively (all P < .05). Alcohol-associated HCC had a lower likelihood of Barcelona Clínic Liver Cancer C stage (0/A) (OR, 0.7; 95% CI, 0.6-0.9; P = .018) and curative therapy (24.5% vs 33.9%; OR, 0.7; 95% CI, 0.5-0.9; P = .003), and higher mortality (HR, 1.3; 95% CI, 1.1-1.5; P = .012) when compared with other causes. CONCLUSIONS: Alcohol-associated HCC is associated with lower surveillance rates, more advanced BCLC stage, lower likelihood of receiving curative therapy, and poorer survival. These data call for measures to reduce heavy alcohol consumption and improve strategies for effective HCC surveillance in high-risk individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansPrevalenceGlobal HealthMaleFemale

Stichwörter der Autor:innen

Alcohol-Associated Liver DiseaseCurative TherapyLiver CancerSurvival

Autor:innen und Institutionen

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery, National University Hospital, Singapore.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Biostatistics & Modelling Domain, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
  • Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore.
  • Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery, National University Hospital, Singapore; Division of Surgical Oncology, National University Cancer Institute, Singapore; National University Centre…

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIAAA NIH HHS

Zitieren

APA

Zeng, R. W., Ong, C. E. Y., Ong, E. Y. H., Chung, C. H., Lim, W. H., Xiao, J., Danpanichkul, P., Law, J. H., Syn, N., Chee, D., Kow, A. W. C., Lee, S. W., Takahashi, H., Kawaguchi, T., Tamaki, N., Dan, Y. Y., Nakajima, A., Wijarnpreecha, K., Muthiah, M. D., …, & Huang, D. Q. (2024). Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 22(12), 2394-2402.e15. https://doi.org/10.1016/j.cgh.2024.06.026

Vancouver

Zeng RW, Ong CEY, Ong EYH, Chung CH, Lim WH, Xiao J, et al. Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology. 2024;22(12):2394-2402.e15. doi:10.1016/j.cgh.2024.06.026

BibTeX
@article{Zeng2024,
  author = {Zeng, Rebecca Wenling and Ong, Christen En Ya and Ong, Elden Yen Hng and Chung, Charlotte Hui and Lim, Wen Hui and Xiao, Jieling and Danpanichkul, Pojsakorn and Law, Jia Hao and Syn, Nicholas and Chee, Douglas and Kow, Alfred Wei Chieh and Lee, Sung Won and Takahashi, Hirokazu and Kawaguchi, Takumi and Tamaki, Nobuharu and Dan, Yock Young and Nakajima, Atsushi and Wijarnpreecha, Karn and Muthiah, Mark D and Noureddin, Mazen and Loomba, Rohit and Ioannou, George N and Tan, Darren Jun Hao and Ng, Cheng Han and Huang, Daniel Q},
  title = {Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {12},
  pages = {2394--2402.e15},
  doi = {10.1016/j.cgh.2024.06.026}
}
Kostenlos starten →